Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUCMSC-EVs in Interstitial Lung Disease
NCT07570836Phase 1Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of human umbilical cord mesenchymal stem cell-derived extracellular vesicles in interstitial lung disease (ILD) (3 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Incidence and Severity of Adverse Events at 12 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cell-derived extracellular vesicles
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07570836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570836.